Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cutaneous Squamous Cell Carcinoma: early-phase trial registry
11 of 19 indexed Cutaneous Squamous Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 11 currently recruiting · #902 of 28,707 conditions by registered trial count
Cutaneous Squamous Cell Carcinoma: 19 US clinical trials tracked, 11 recruiting.
Cutaneous Squamous Cell Carcinoma is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 2 of these trials.
Enrollment posture brief
Registry condition cutaneous-squamous-cell-carcinoma
OPEN 11 | RECR 58% | LATE 1 | EARLY 15 | RANK #902 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Burnout (58% recruiting · 19 trials)
Cutaneous Squamous Cell Carcinoma lists 11 open slots (58% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cutaneous Squamous Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cutaneous Squamous Cell Carcinoma is recruiting above its size-band peers.
11 of 19 indexed trials (57.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cutaneous Squamous Cell Carcinoma trials is spread across many organizations.
H. Lee Moffitt Cancer Center and Research Institute accounts for 2 of 19 trials (10.5%). 17 distinct sponsors appear on at least one study for this condition label.
-
Most Cutaneous Squamous Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 48 among the 19 trials that report a genuine target (sentinel values excluded). 16 of those (84.2%) plan for fewer than 100 participants.
-
Cutaneous Squamous Cell Carcinoma research is mostly interventional.
18 interventional and 1 observational studies make up this index (94.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
NCT04429542
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Ankyra Therapeutics
NCT06171750
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
Indiana University
NCT05108090
ctDNA in Cutaneous Squamous Cell Carcinoma
Massachusetts Eye and Ear Infirmary
NCT06875609
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT05859074
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
Falo, Louis, MD
NCT05377905
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen
NCT05076760
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
M.D. Anderson Cancer Center
NCT06567314
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
AdventHealth Translational Research Institute
NCT06008977
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
The Center for Clinical and Cosmetic Research
NCT06577311
TIL Therapy in cSCC and MCC
Karam Khaddour, MD, MS
NCT07288073
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
NCT03969004
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Replimune
NCT04050436
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
NCT05565417
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04975152
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Memorial Sloan Kettering Cancer Center
NCT05574101
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
NCT05358938
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
NCT04616248
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
NCT03082534
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cutaneous Squamous Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cutaneous Squamous Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cutaneous Squamous Cell Carcinoma page
19 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Cutaneous Squamous Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most Cutaneous Squamous Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cutaneous Squamous Cell Carcinoma condition card totals 19 registered trials; most-linked intervention Cemiplimab; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.